You need JavaScript to view this

Superparamagnetic iron oxides for MRI

Journal Article:

Abstract

Pharmaceutical iron oxide preparations have been used as MRI contrast agents for a variety of purposes. These agents predominantly decrease T2 relaxation times and therefore cause a decrease in signal intensity of tissues that contain the agent. After intravenous administration, dextran-coated iron oxides typically accumulate in phagocytic cells in liver and spleen. Clinical trials have shown that iron oxide increases lesion/liver and lesion/spleen contrast, that more lesions can be depicted than on plain MRI or CT, and that the size threshold for lesion detection decreases. Decreased uptake of iron oxides in liver has been observed in hepatitis and cirrhosis, potentially allowing the assessment of organ function. More recently a variety of novel, target-specific monocrystalline iron oxides compounds have been used for receptor and immunospecific images. Future development of targeted MRI contrast agents is critical for organ- or tissue-specific quantitative and functional MRI. (orig.)
Authors:
Weissleder, R; [1]  Reimer, P [1] 
  1. MGH-NMR Center, Dept. of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA (United States)
Publication Date:
Jun 01, 1993
Product Type:
Journal Article
Reference Number:
SCA: 550602; PA: DEN-95:0F8397; EDB-95:073493; SN: 95001386222
Resource Relation:
Journal Name: European Radiology; Journal Volume: 3; Journal Issue: 3; Other Information: PBD: Jun 1993
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; NMR IMAGING; CONTRAST MEDIA; IRON OXIDES; DIAGNOSTIC TECHNIQUES; FERRITE; MAGNETITE; LIVER; KIDNEYS; SPLEEN; BONE MARROW; LYMPH NODES; GASTROINTESTINAL TRACT; BRAIN; MYOCARDIUM; ANTIBODIES; ACCURACY
OSTI ID:
42165
Country of Origin:
Germany
Language:
English
Other Identifying Numbers:
Journal ID: EURAE3; ISSN 0938-7994; TRN: DE95F8397
Submitting Site:
DEN
Size:
pp. 198-212
Announcement Date:

Journal Article:

Citation Formats

Weissleder, R, and Reimer, P. Superparamagnetic iron oxides for MRI. Germany: N. p., 1993. Web. doi:10.1007/BF00425895.
Weissleder, R, & Reimer, P. Superparamagnetic iron oxides for MRI. Germany. doi:10.1007/BF00425895.
Weissleder, R, and Reimer, P. 1993. "Superparamagnetic iron oxides for MRI." Germany. doi:10.1007/BF00425895. https://www.osti.gov/servlets/purl/10.1007/BF00425895.
@misc{etde_42165,
title = {Superparamagnetic iron oxides for MRI}
author = {Weissleder, R, and Reimer, P}
abstractNote = {Pharmaceutical iron oxide preparations have been used as MRI contrast agents for a variety of purposes. These agents predominantly decrease T2 relaxation times and therefore cause a decrease in signal intensity of tissues that contain the agent. After intravenous administration, dextran-coated iron oxides typically accumulate in phagocytic cells in liver and spleen. Clinical trials have shown that iron oxide increases lesion/liver and lesion/spleen contrast, that more lesions can be depicted than on plain MRI or CT, and that the size threshold for lesion detection decreases. Decreased uptake of iron oxides in liver has been observed in hepatitis and cirrhosis, potentially allowing the assessment of organ function. More recently a variety of novel, target-specific monocrystalline iron oxides compounds have been used for receptor and immunospecific images. Future development of targeted MRI contrast agents is critical for organ- or tissue-specific quantitative and functional MRI. (orig.)}
doi = {10.1007/BF00425895}
journal = {European Radiology}
issue = {3}
volume = {3}
journal type = {AC}
place = {Germany}
year = {1993}
month = {Jun}
}